within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AD02_Tacrolimus;
model Tacrolimus 
   extends Pharmacolibrary.Drugs.ATC.L.L04AD02;

  annotation(Documentation(
    info ="<html><body><p>Tacrolimus is an immunosuppressant macrolide used primarily to prevent organ transplant rejection and to treat certain autoimmune diseases. It acts by inhibiting calcineurin, thus suppressing T-lymphocyte activation. It is approved and remains widely used in clinical practice, particularly for kidney, liver, and heart transplant recipients.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters reported for adult kidney transplant recipients following oral administration in the early post-transplant period, population containing both sexes.</p><h4>References</h4><ol><li><p>Venkataramanan, R, Swaminathan, A, Prasad, T, Jain, A, Zuckerman, S, Warty, V, McMichael, J, Lever, J, Burckart, G, &amp; Starzl, T (1995). Clinical pharmacokinetics of tacrolimus. <i>Clinical pharmacokinetics</i> 29(6) 404–430. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199529060-00003&quot;>10.2165/00003088-199529060-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8787947/&quot;>https://pubmed.ncbi.nlm.nih.gov/8787947</a></p></li><li><p>Martial, LC, Biewenga, M, Ruijter, BN, Keizer, R, Swen, JJ, van Hoek, B, &amp; Moes, DJAR (2021). Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. <i>British journal of clinical pharmacology</i> 87(11) 4262–4272. DOI:<a href=&quot;https://doi.org/10.1111/bcp.14842&quot;>10.1111/bcp.14842</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33786892/&quot;>https://pubmed.ncbi.nlm.nih.gov/33786892</a></p></li><li><p>Lee, KW, Kim, TH, Lee, JB, Kim, KS, Park, JB, Gershkovich, P, Yoo, SD, Shin, S, Shin, BS, &amp; Kim, SJ (2019). Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <i>Journal of pharmacological sciences</i> 139(2) 65–71. DOI:<a href=&quot;https://doi.org/10.1016/j.jphs.2018.05.013&quot;>10.1016/j.jphs.2018.05.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30573325/&quot;>https://pubmed.ncbi.nlm.nih.gov/30573325</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Tacrolimus;
